Pharmafile Logo
Pharmafocus logo
Advanced Search

Oxford Biotherapeutics

Showing 8 posts of 8 posts found.

Tech platform company WuXi Biologics inks deal with cancer specialist Oxford BioTherapeutics worth $450m

December 12, 2018
Research and Development Cancer, Oxford Biotherapeutics, WuXi Biologics, alliance, deal, oncology

Clinical stage oncology firm Oxford BioTherapeutics has signed a deal with the open-access biologics technology platform company WuXi Biologics, in …

News
bryan_morton

Oxford BioTherapeutics hires chairman

June 27, 2013
Manufacturing and Production, Research and Development, Sales and Marketing Oxford Biotherapeutics, morton

Biotech firm Oxford BioTherapeutics has appointed Bryan Morton to be the company’s new non-executive chairman. Morton has over 30 years’ …

Appointment

Oxford BioTherapeutics appoints new chief operations officer

May 3, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Oxford Biotherapeutics

Oxford BioTherapeutics (OBT) has appointed Dr Esteban Pombo-Villar as its new chief operations officer (COO). In this position he will …

Appointment

Oxford BioTherapeutics appoints C. Glenn Begley as a senior clinical advisor

January 17, 2012
Business Services, Research and Development, Sales and Marketing C. Glenn Begley, Oxford Biotherapeutics

Oxford BioTherapeutics has appointed C. Glenn Begley as a senior clinical advisor and non-executive director of the firm.  Dr Begley, …

Appointment

Sanofi buys into cancer antibody research

January 26, 2011
Research and Development Cancer, Oxford Biotherapeutics, Sanofi, Sanofi-Aventis, antibody drug conjugate, cancer research

Sanofi-Aventis has bought a global licence to develop and commercialise one of Oxford BioTherapeutics’ (OBT) oncology programmes. For an undisclosed …

News

Michael Moore, chairman, Oxford BioTherapeutics

January 11, 2010
Research and Development Oxford Biotherapeutics, Piramed, appointment, research and development

Oxford BioTherapeutics (OBT) has appointed Dr Michael Moore non-executive chairman. He joins the company following five years spent at UK …

Appointment

Oxford BioTherapeutics appoints Dr Jim Cornett, Dr Jon Terrett and Dr Mike Gresser

December 2, 2009
Research and Development Oxford Biotherapeutics, appointment, research and development

Oxford BioTherapeutics has expanded its US operations, recruiting a number of senior industry leaders.Dr Jim Cornett will head up operations …

Appointment

GSK signs oncology deal with UK biotech

May 18, 2009
Research and Development, Sales and Marketing GSK, Oxford Biotherapeutics

GSK has struck a deal with Oxford BioTherapeutics to develop therapies for primary, metastatic and recurring forms of cancer. The …

News
The Gateway to Local Adoption Series

Latest content

Thermo Fisher opens new distribution centre in Ireland

March 12, 2026

Altimetrik appoints Dhirendra Nath as Chief Human Resources Officer

March 12, 2026

Kindeva appoints Mike Cowhig as Chief Legal Officer

March 11, 2026

DiaMedica gets regulatory clearance from Health Canada for phase 2 preeclampsia study

March 11, 2026

Abselion establishes a US subsidiary in Massachusetts 

March 10, 2026